Onco'Zine, an online journal and digital platform covering all aspects of oncology and hematology, published by Sunvalley Communication, LLC, is pleased that Dhruvajyoti (Dhruv) Roy, Ph.D., Director of Technology at Helio Genomics, Inc. has joined the publication's Editorial Advisory Board.
CHANDLER, Ariz., Aug. 19, 2022 /PRNewswire-PRWeb/ -- Today, Onco'Zine, an online, science-driven, journal and digital platform covering all aspects of oncology and hematology, published by Sunvalley Communication, LLC, confirms that Dhruvajyoti (Dhruv) Roy, Ph.D. has joined the journal's editorial advisory board.
As a member of the editorial advisory board, Dr. Roy will be helping to guide the publication's editorial staff to ensure that the publication's science-driven content stays atop critical topics, issues, and concerns that affect the oncology (academic, research & development and clinical) community and the larger biotechnology industry sector.
"Dr. Roy's experience will be invaluable as we accelerate our global editorial mission and grow the journal. We are excited to have Dhruv on our Editorial Advisory Board and look forward to working closely with him," said Peter Hofland, Ph.D., the journal's Executive Editor and Publisher.
"We admire Dr. Roy's expertise in liquid biopsies as well as his keen and intimate understanding of the early diagnosis of cancer. Dr. Roy brings unique perspectives and provides deep understanding of major critical topics to recognize developments that are critical and will provide valuable insights to support the growth and advancement of the journal," he added.
"I am privileged to be a member of the Scientific Advisory Board for OncoZine and to be associated with such an esteemed team of academic and industry experts. Collectively, we will aim to guide OncoZine through the advancement of its current mission while exploring the possibilities of the journal's scopes," Dhruvajyoti (Dhruv) Roy, Ph.D noted.
"The goal of OncoZine is to publish potentially transformative oncology news as well as the latest research highlights and clinical issues at the intersection of biomedical science and clinical practice that confront us in this new era of cancer care. I am excited to collaborate with this team of clinicians, translational researchers, clinical trial experts and oncology pioneers to guide the editorial decision and strategy for the journal," Dr. Roy added.
Dhruvajyoti (Dhruv) Roy, Ph.D., is the Director of Technology at Helio Genomics, Inc., an AI-driven healthcare company focused on commercializing early cancer detection tests from a simple blood draw. He received his Ph.D. in Chemistry and Nano-biotechnology from the Pohang University of Science and Technology (POSTECH) in South Korea. Dr. Roy served as a lead scientist and directed multiple research projects as a key research scientist for collaborations with multi-disciplinary research/scientific teams and professionals including major pharmaceutical and diagnostic companies. He has > 12 years of substantive research experience in biotechnology combining extensive technical, bio-analytical and interpretive skills with practical laboratory experience on Next-generation Sequencing (NGS) and Liquid Biopsies including CTCs, exosomes, and circulating cell free nucleic acid-based tests.
Dr. Roy is a member of the American Society of Clinical Oncology (ASCO), a senior member of IEEE and Sigma Xi member of the Scientific Research Honor Society. He is also associated with several prestigious peer-reviewed journals as a reviewer, editor and editorial board member, including Langmuir, Lab on a Chip, Analytical and Bioanalytical Chemistry, Journal of Biosensors Biomarkers and Diagnostics, Molecular Cancer Therapeutics, Clinical Cancer Research, Translational Oncology, and others.
About Onco'Zine
Onco'Zine is an online journal and digital platform covering all aspects of oncology and hematology. The primary focus of Onco'Zine is to inform, educate, and support physicians and healthcare professionals treating cancer patients. The journal delivers a full spectrum of news and information, reporting on current research and development in oncology and hematology. Onco'Zine has a robust and stable audience. in 2020 the journal averaged more than 34,000 monthly readers, with 80% of our readers being healthcare professionals focusing on oncology and hematology. The journal, published by Sunvalley Communication LLC, is part of an online network of medical news and educational media providing cutting-edge resources in oncology and hematology.
The network also includes ADC Review | Journal of Antibody-drug Conjugates, a peer review journal focusing on the development of antibody-drug Conjugates (ADC), the radio and podcast series The Onco'Zine Brief, the educational video series Changing Strategies in the War on Cancer, industry focused directories, including the ADC Directory and Oncology Directory, the ADC Drug Map (Antibody-drug Conjugates) and a new peer reviewed journal focusing on the development of Chimeric Antigen Receptor T-cells (CAR T-cell) therapies, the International Journal of CAR T-cell Therapy (scheduled to be launched in 2023). For more information about advertising and sponsoring opportunities download the media kit.
Editorial Advisory Board
The editorial advisory board of Onco'Zine includes physicians (including oncologists and hematologists), scientists, experts from the life science, biotech, pharmaceutical industry, academia, Key Opinion Leaders (KOL), and regulators, each with a broad range of backgrounds and expertise in oncology and hematology.
The editorial advisory board plays a major role advising on journal policy and scope and helps in maintaining the accuracy, credibility and quality of the journal, and, together with the editorial team, helps set the tone and direction of the publication's editorial policy. The members of the editorial advisory board also help the editorial team to determine the content of the journal (which includes identifying topics of interest and potential article ideas), attract new authors and submissions, review (unsolicited) manuscripts submitted for inclusion in the journal, promote the journal to their colleagues and peers and provide a network of potential contributors/authors.
About Sunvalley Communication LLC
Sunvalley Communication LLC is a global, high-science, medical marketing and corporate communications agency. Sunvalley Communication's branded international network provides innovative, customized, and professional physician and patient education, publication development and management, digital and interactive marketing, webinars, broadcast and podcast solutions, as well as advertising, strategic media planning and buying, direct to patient and promotional marketing, public relations and other specialty communications services for healthcare, biotech and pharmaceutical companies active in oncology, hematology, and cancer supportive care.
Source: Sunvalley Communication, LLC
Media Contact
Kindra Deneau (Consultant), Sunvalley Communication, LLC, +1 (480) 626 7218, [email protected]
SOURCE Sunvalley Communication, LLC
Share this article